Recruiting
Phase 2

Talazoparib and Low-Dose Temozolomide in Treating Participants With Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer

Sponsor:

Jonsson Comprehensive Cancer Center

Code:

NCT03672773

Conditions

Recurrent Extensive Stage Small Cell Lung Carcinoma

Refractory Extensive Stage Small Cell Lung Carcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Talazoparib

Temozolomide

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information